Filing Details

Accession Number:
0001127602-12-012020
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-03-28 19:16:50
Reporting Period:
2012-03-26
Filing Date:
2012-03-28
Accepted Time:
2012-03-28 18:16:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
850693 Allergan Inc AGN Pharmaceutical Preparations (2834) 951622442
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298861 M Trevor Jones 2525 Dupont Drive
Irvine CA 92612
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-03-26 2,000 $94.34 22,960 No 4 S Direct
Common Stock Acquisiton 2012-03-26 1,000 $36.49 23,960 No 4 M Direct
Common Stock Disposition 2012-03-26 1,000 $94.29 22,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nonemployee Director Stock Option (Right to Buy) Disposition 2012-03-26 1,000 $0.00 1,000 $36.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,000 2006-04-26 2015-04-26 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 10, 2012.
  2. The price reported in Column 4 is the weighted average price. These shares wee sold in multiple transactions at prices ranging from $94.28 to $94.38, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, full informatin regarding the number of shares sold at each price within the range set forth in this footnote.
  3. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $94.22 to $94.45, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  4. The per share exercise price is the closing price of Allergan common stock as of April 25, 2005, rounded upwards to three decimals.
  5. Option is fully vested and exercisable on the one year (1) year anniversary of its grant.